Eclipse Life Sciences Announces Positive Results for EC-104 in Diabetic Macular Edema Trial
News related to:Eclipse Life Sciences, Inc · 2 min read
RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2026 /CourierPR/ -- Eclipse Life Sciences, a privately held clinical-stage biopharmaceutical company, has announced positive topline results from its Phase 2 BETTIS-1 clinical trial evaluating EC-104 for the treatment of diabetic macular edema (DME). The trial compared EC-104, a novel, completely biodegradable intravitreal corticosteroid implant, to Ozurdex®. EC-104 is engineered to deliver approximately six months of durable drug release.
The BETTIS-1 trial met its primary endpoint, demonstrating a favorable safety profile across both EC-104 formulations compared to Ozurdex®. Secondary endpoints showed superior clinically meaningful and durable improvement in both best corrected visual acuity and OCT central subfield thickness at 24 weeks, when compared to Ozurdex®. The superiority of EC-104 was demonstrated in a study population of subjects with a previous suboptimal response to anti-VEGF therapy, which represents a significant unmet need and commercial opportunity.
The BETTIS-1 trial involved two clinical trials comparing EC-104 to Ozurdex®. Both EC-104 formulations demonstrated a sustained reduction in central subfield thickness (CST) through 24 weeks, consistent with the six-month release profile of the implant. Patients with prior corticosteroid tolerance maintained acceptable intraocular pressure (IOP) outcomes in both formulation arms.
With strong Phase 2 data, Eclipse Life Sciences is exploring partnership opportunities to accelerate Phase 3 initiation and global commercialization. EC-104’s profile positions it as a differentiated entrant in the multi-billion-dollar DME market where durability and efficacy drive adoption.
In addition to EC-104, Eclipse Life Sciences is advancing EC-303 for intermediate dry age-related macular degeneration (AMD) and EC-501, a six-month anti-VEGF therapy candidate for wet AMD, DME, and macular edema following retinal vein occlusion (RVO).
Eclipse Life Sciences plans to engage with regulatory authorities to discuss Phase 3 development of EC-104 and expects to initiate a pivotal program in 2027. Full BETTIS-1 data will be presented at an upcoming ophthalmology conference and will be submitted for publication in a peer-reviewed journal.
The company’s commitment to developing innovative therapies for ophthalmic diseases is evident in its ongoing research and development efforts. EC-104’s potential to reduce treatment burden and its strong safety profile make it a promising candidate for patients with DME. The company’s pipeline includes other candidates such as EC-303 and EC-501, which are designed to address different aspects of retinal diseases.
Eclipse Life Sciences’ focus on advancing EC-104 and other therapies underscores its dedication to improving patient outcomes and addressing unmet needs in the ophthalmology field. The positive results from the BETTIS-1 trial are a significant step forward in the company’s journey to bring effective and durable treatments to patients suffering from DME and other retinal diseases.